Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $9.4 million.

  • Akebia Therapeutics' Cost of Revenue fell 3374.06% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.3 million, marking a year-over-year decrease of 2307.49%. This contributed to the annual value of $63.2 million for FY2024, which is 1479.72% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Cost of Revenue is $9.4 million, which was down 3374.06% from $9.9 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Cost of Revenue peaked at $52.5 million during Q2 2021, and registered a low of -$3.4 million during Q4 2022.
  • Moreover, its 5-year median value for Cost of Revenue was $18.0 million (2023), whereas its average is $20.6 million.
  • In the last 5 years, Akebia Therapeutics' Cost of Revenue tumbled by 10719.97% in 2022 and then surged by 64432.78% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Cost of Revenue (Quarter) stood at $47.6 million in 2021, then crashed by 107.2% to -$3.4 million in 2022, then surged by 644.33% to $18.7 million in 2023, then grew by 9.11% to $20.4 million in 2024, then tumbled by 53.93% to $9.4 million in 2025.
  • Its Cost of Revenue was $9.4 million in Q3 2025, compared to $9.9 million in Q2 2025 and $7.6 million in Q1 2025.